Skip to main content
Cancer Informatics logoLink to Cancer Informatics
. 2014 Nov 2;13:125–129. doi: 10.4137/CIN.S20237

Correction to: Prognostic Features of Signal Transducer and Activator of Transcription 3 in an ER(+) Breast Cancer Model System

Li-Yu D Liu 2,*, Li-Yun Chang 1,*, Wen-Hung Kuo 3, Hsiao-Lin Hwa 1, Yi-Shing Lin 4, Meei-Huey Jeng 6, Don A Roth 7, King-Jen Chang 3,5, Fon-Jou Hsieh 1,8,
PMCID: PMC4218890  PMID: 25402670

The authors of Li-Yu D. Liu, Li-Yun Chang, Wen-Hung Kuo et al. Prognostic features of signal transducer and activator of transcription 3 in an ER(+) breast cancer model system. Cancer Informatics. 2014;13:21–45. doi: 10.4137/CIN.S12493. recently brought to the attention of the Editor in Chief, Dr. J. T. Efird, corrections they wished to make to the paper. The Editor in Chief reviewed these with reference to applicable Committee on Publication Ethics guidelines and determined that publication of a separate corrigendum was an appropriate response to the authors’ request. The authors’ full statement is given hereafter.

We, as the authors of the paper “Prognostic features of signal transducer and activator of transcription 3 in an ER (+) breast cancer model system”, published in Cancer Informatics 2014:13 21–45, wish to correct Figures 3F, 7A, 7B, S6.2–6.3, S7.1–7.5 and Tables 2, 3.

Figure 3F.

Figure 3F

Figure 7A,B.

Figure 7A,B

Table 2.

GENE SYMBOL (FEATURE NO.) INCREASED EXPRESSION LEVEL P VALUE PATHWAYS
ABL1 (8019) poor prognosis 0.046 ERBB2, PDGFRB, cell cycle and angiogenesis
IGF2R (1723) poor prognosis 0.048 angiogenesis
PRKCB1 (6676) good prognosis 0.033 ERBB2 and VEGF
MAP2 K4 (18964) good prognosis 0.034 ERBB2
NRG1 (11559) good prognosis 0.011 ERBB2
LYN (19236) poor prognosis 0.001 PDGFRB and angiogenesis
STAT3 (4386) poor prognosis 0.028 PDGFRB and angiogenesis
STAT3 (15013) poor prognosis 0.002 PDGFRB and angiogenesis
VEGFA (1135) poor prognosis 0.02 VEGF and angiogenesis
VEGFA (15367) poor prognosis 0.008 VEGF and angiogenesis
OIP5 (16433) poor prognosis 0.013 FOXC1 network
NCK2 (3851) poor prognosis 0.029 ERBB2 and PDGFRB
LDHB (20259) poor prognosis 0.038 Warburg effect
GRB2 (16731) poor prognosis 0.019 ERBB2 and PDGFRB
*NANOG (C12928.2) good prognosis 0.024 EMT
POU5F1 (6057) good prognosis 0.02 EMT
GRB2 (1952) poor prognosis 0.03 ERBB2 and PDGFRB

Table 3.

GENE SYMBOL REGULATION STATUS BIOCHEMICAL PATHWAY PROGNOSIS REGULATORS
GRB2 up ERBB2 and PDGFRB poor MYC and STAT3
CDKN1A up p53, cell cycle and ERBB2 poor MYC and STAT3
ARAF up ERBB2 poor MYC and STAT3
NCK2 up ERBB2 and PDGFRB poor MYC and STAT3
PAK6 up ERBB2 good MYC and STAT3
KRAS up ERBB2 and VEGF good MYC and STAT3
STAT3 up PDGFRB and angiogenesis poor MYC and STAT3
ELK1 up FOXC1 network and ERBB2 good MYC and STAT3
OIP5 down FOXC1 network good MYC and STAT3
*NRAS up ERBB2 poor STAT3
LYN up PDGFRB and angiogenesis poor MYC and STAT3
VEGFA up angiogenesis poor MYC and STAT3

We made unexpected mistakes during generating genome-wide data of 90th percentile Kaplan-Meier survival analysis on the gene of interest using R package. We have generated multiple sets of survival curves beginning with the earlier publications. To the best of our knowledge, all of them are correct except for 72 A cohort and a few data in 90 A cohort in this paper. The new Figure 3F, Tables 23 and Figures S6.2–6.3 have the corrected data, marked in red in Tables 23.

Additionally, we have made new Figures 7A and B to replace the old ones to be consistent with the original text.

In some instances, the text of the article also reflects errors in the data, and is hereby corrected as follows:

Page 23, right column.

This sentence from the original article:

Kaplan-Meier survival analyses21 were done using the “survival” package in R (version 2.15.1) for the gene profiles of 90 A cohort, 91 A cohort, 181 A cohort or the extracted gene pools of interest in the assigned cohorts.

is corrected to read as follows:

Kaplan-Meier survival analyses21 were done using the “survival” package in R (version 2.15.1) for the gene profiles of 90 A cohort, 72 A cohort, 181 A cohort or the extracted gene pools of interest in the assigned cohorts.

Page 30, legends of tables 2 and 3

To be consistent with new Figure 3F, the legend of Table 2 from the original article:

Table 2. The prognostic values for inferred target genes of STAT3 and MYC in the 90 A cohort.

is corrected to read as follows:

Table 2. The prognostic values for inferred target genes of STAT3 and MYC or of *STAT3 in the 90 A cohort (Fig. 3F).

To be consistent with new Figure 3F, the legend of Table 3 from the original article:

Table 3. The prognostic values for inferred target genes of STAT3 and MYC in the 72 A cohort.

is corrected to read as follows:

Table 3. The prognostic values for inferred target genes of STAT3 and MYC or of *STAT3 in the 72 A cohort (Fig. 3F).

Page 31, right column.

This sentence from the original article:

High levels of IDH3G are a favorable prognosis predictor in 72 A cohort (Table 3).

should be regarded as deleted.

Page 35, left column

This sentence from the original article:

Surprisingly, STAT3 regulates 59% (60/101) of ERBB2 signaling molecules in the 90 A cohort.

is corrected to read as follows:

Surprisingly, STAT3 regulates 59% (60/101) of ERBB2 signaling molecules in the 90 A cohort (Table S4.12).

This sentence from the original article:

The expression patterns of these signaling molecules shown in heatmaps (Fig. 7B) indicate that STAT3 mediated regulation of these 6 signaling molecules (PRKCB1, MAP2K4, NRG1, NCK2, ABL1 and GRB2) provides a good prognostic indicator in the 90 A cohort (Table 2).

is corrected to read as follows:

The expression patterns of these signaling molecules shown in heatmaps (Fig. 7B) indicate that STAT3 mediated regulation of these 5 signaling molecules (MAP2K4, NRG1, NCK2, ABL1 and GRB2) provides a poor prognostic indicator in the 90 A cohort (Table 2).

Page 36, left column

This sentence from the original article: For instance, we found the expression levels of GRB2, NCK2, STAT3, PRKCB1, MAP2K4, ABL1, IGF2R, LYN, and VEGFA in the STAT3 network to be predictors for poor clinical outcome in the 90 A cohort.

is corrected to read as follows:

For instance, we found the expression levels of NANOG, GRB2, NCK2, STAT3, PRKCB1, MAP2K4, ABL1, IGF2R, LYN, and VEGFA in the STAT3 network to be predictors for poor clinical outcome in the 90 A cohort.

This sentence from the original article:

Alternately, the expression levels of NANOG, OIP5, LDHB, NRG1 and POU5F1 in the STAT3 network are predicted to be good prognostic factors in the 90 A cohort (Fig. 3F and Table 2).

is corrected to read as follows:

Alternately, the expression levels of OIP5, LDHB, NRG1 and POU5F1 in the STAT3 network are predicted to be good prognostic factors in the 90 A cohort (Fig. 3F and Table 2).

This sentence from the original article:

Moreover, there are 6 poor and 5 good prognostic factors in the STAT3 network of 72 A cohort (Fig. 3F and Table 3).

is corrected to read as follows:

Moreover, there are 8 poor and 4 good prognostic factors in the STAT3 network of 72 A cohort (Fig. 3F and Table 3).

Page 37, right column

This sentence from the original article:

We found 9 poor prognostic factors and 5 good prognostic factors of the STAT3 network in the 90 A cohort (Fig. 3F and Table 2).

is corrected to read as follows:

We found 10 poor prognostic factors and 4 good prognostic factors of the STAT3 network in the 90 A cohort (Fig. 3F and Table 2).

Page 41, right column

These sentences from the original article:

It contains relatively high levels of GRB2, LYN, IGF2R, VEGFA, STAT3, NCK2, OIP5 and ABL1 and low levels of MAP2K4, PRKCB, POU5F1 and NRG1, indicating poor prognosis. Low levels of LDHB and NANOG predict good prognosis.

are corrected to read as follows:

It contains relatively high levels of GRB2, LYN, IGF2R, VEGFA, STAT3, NCK2, OIP5 and ABL1 and low levels of MAP2K4, PRKCB, POU5F1, NRG1 and NANOG, indicating poor prognosis. Relative low levels of LDHB predict good prognosis.

Supplementary Files

Please also view the Supplementary Files PDF, which contains corrected versions of Supplementary Figures S6.2–S6.3 and S7.1–S7.5.

Footnotes

ACADEMIC EDITOR: JT Efird, Editor in Chief

FUNDING: The original article was funded by grants (NSC95-2314-B-002-255-MY3 and NSC982314-B-002-093-MY2) to Fon-Jou Hsieh.

COMPETING INTERESTS: Authors disclose no potential conflicts of interest.

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials


Articles from Cancer Informatics are provided here courtesy of SAGE Publications

RESOURCES